Acquisition Completed

Day One Biopharmaceuticals acquisition of Mersana Therapeutics

NASDAQ: MRSN · US$25.00 per share

Advisers

Mersana Therapeutics

Target

Financial adviser
TD Securities (as TD Cowen)
Legal adviser

Day One Biopharmaceuticals

Acquirer

Financial adviser
Legal adviser
Target
Mersana Therapeutics
Acquirer
Day One Biopharmaceuticals
Target based in
United States
Buyer based in
United States
Completed
6 Jan 2026
Sector
Biotech
Tags
Biotech, Oncology, Drug Development

In the league tables

Similar deals

All biotech deals →

Sources

Suggest a correction

A missing adviser, a wrong role or a different outcome. A link to a public source helps.